Fig. 5

UCMSCs-Tandab(IL-6/CD20) inhibited the proliferation of SU-DHL-2/4. (A-D) CCK-8 assay for evaluating the cell viability of SU-DHL-2 (A and C) or SU-DHL-4 (B and D) after different treatments (the supernatants of UCMSCs-Tandab(IL-6/CD20), Rituximab (1000 ng/ml, 100 ng/ml, 10 ng/ml), Tocilizumab(10 ng/ml) and mixture of Rituximab and Tocilizumab (5 and 5 ng/ml)) without the presence of PBMCs. (E–H) CCK-8 assay for evaluating the viability of SU-DHL-2 (E and G) or SU-DHL-4 (F and H) after different treatments (the supernatants of UCMSCs-Tandab(IL-6/CD20), Rituximab(1000 ng/ml, 100 ng/ml, 10 ng/ml), Tocilizumab(10 ng/ml) and mixture of Rituximab and Tocilizumab (5 and 5 ng/ml)) with the presence of PBMCs. n = 6 for each group. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001